Global Osteogenesis Imperfecta Treatment Market, By Drug Class (Teriparatide, Denosumab, Others), Route of Administration (Oral, Intravenous, Subcutaneous),End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
The osteogenesis imperfecta treatment market is expected to gain growth at a potential rate of 2.40% in the forecast period of 2021 to 2028. The rise in research and development activities is the factor responsible for the market growth.
Osteogenesis imperfecta (OI) is a kind of orphan disease group, characterized by unstable degrees of skeletal frailty such as low bone mass and a tendency to fracture. This condition is caused because of the mutations in the COL1A1 or COL1A2 gene which encodes the alpha chains of collagen produced by osteoblasts.
The increase in number of patients with osteogenesis imperfecta is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the high demand for novel therapies for osteogenesis imperfecta treatment and the licensing agreement and strategic collaborations among key industry players are also predictable to enhance the osteogenesis imperfecta treatment market growth. Furthermore, the high adoption of new products and rise in the number of clinical trials are also projected to drive the market growth rate.
In addition, the strong product pipeline for osteogenesis imperfecta, rise in the R&D initiatives to develop novel therapies and treatment and favorable government support are likely to create various new opportunities that will impact this osteogenesis imperfecta treatment market growth in the forecast period of 2021 to 2028.
However, the lack of trained professionals and the non-availability of effective treatment for osteogenesis imperfecta are expected to act as major restraints towards the growth of the osteogenesis imperfecta treatment market, whereas the lack of awareness can further challenge the growth of the target market in the above mentioned forecast period.
This osteogenesis imperfecta treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the osteogenesis imperfecta treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Osteogenesis Imperfecta Treatment Market Scope and Market Size
Osteogenesis imperfecta treatment market is segmented on the basis of drug class, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug class, the osteogenesis imperfecta treatment market can be segmented into teriparatide, denosumab and others.
- Based on route of administration, the osteogenesis imperfecta treatment market can be segmented into oral intravenous and subcutaneous.
- On the basis of end user, the osteogenesis imperfecta treatment market can be segmented into hospitals, homecare, specialty clinics and others.
- Based on distribution channel, the osteogenesis imperfecta treatment market can be segmented into hospital pharmacies, retail pharmacies and online pharmacies.
Osteogenesis Imperfecta Treatment Market Country Level Analysis
Osteogenesis imperfecta treatment market is analyzed and market size information is provided by country by drug class, route of administration, end user and distribution channel as referenced above.
The countries covered in the osteogenesis imperfecta treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the osteogenesis imperfecta treatment market due to the strong presence of major market players and rise in focus on research and development. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the high adoption of new products and increase in number of patients suffering from osteogenesis imperfecta.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Osteogenesis imperfecta treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Osteogenesis Imperfecta Treatment Market Share Analysis
Osteogenesis imperfecta treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to osteogenesis imperfecta treatment market.
The major players covered in the osteogenesis imperfecta treatment market report are Bone Therapeutics SA, CELGENE CORPORATION, Mereo BioPharma Group plc, Eli Lilly and Company, Amgen Inc, Midas Pharma GmbH, LGM Pharma, Cipla Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd, Mylan N.V., Merck & Co., Inc. Aurobindo Pharma, and Jubilant Life Sciences Ltd among other domestic and global players. Osteogenesis imperfecta treatment market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.